MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-07-2024
Country |
 USA |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
85.1 M |
Market Cap[1] |
$ 2.18 B |
EBITDA (LTM) |
$ -185 M |
P/E (LTM) |
- |
P/S (LTM) |
14.41 |
EPS (LTM) |
-2.3 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
AbbVie
ABBV
|
$ 223.98 | -0.53 % | $ 396 B | NYSE,SPB | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.67 | 1.74 % | $ 775 M | Nasdaq Global Select Market |  Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 3.36 | 2.75 % | $ 260 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 210.16 | 4.43 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
Aptorum Group Limited
APM
|
$ 1.33 | -1.48 % | $ 7.25 M | Nasdaq Global Select Market |  China |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.42 | 2.09 % | $ 8.23 B | Nasdaq Capital Market |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.9 | 0.74 % | $ 1.25 B | Nasdaq Global Select Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 90.29 | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Anika Therapeutics
ANIK
|
$ 9.49 | - | $ 139 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.28 | - | $ 14.3 M | Nasdaq Capital Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Biogen
BIIB
|
$ 172.5 | - | $ 25.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.96 | 1.17 % | $ 533 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 581.03 | 2.22 % | $ 44 B | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.29 | -0.31 % | $ 631 M | NYSE American | Israel |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 15.31 | - | $ 1.01 B | Nasdaq Capital Market | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 2.15 | 13.76 % | $ 397 M | Nasdaq Global Market | USA |
 |
BioVie
BIVI
|
$ 1.51 | -4.43 % | $ 2.23 M | Nasdaq Capital Market | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.94 | - | $ 1.8 M | Nasdaq Global Select Market | USA |
 |
Cellectar Biosciences
CLRB
|
$ 3.78 | -5.97 % | $ 46.2 M | Nasdaq Capital Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.44 | 7.92 % | $ 740 M | NYSE | USA |
 |
BioNTech SE
BNTX
|
$ 96.0 | - | $ 27.2 B | Nasdaq Global Select Market |  Germany |
 |
Eloxx Pharmaceuticals
ELOX
|
- | -5.68 % | $ 8.28 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | USA |
 |
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.